Repligen Reports Third Quarter 2024 Financial Results
12 nov. 2024 07h30 HE
|
Repligen Corporation
Q3 2024 Earnings Report
Repligen Corporation to Present at Upcoming Investor Conferences
05 nov. 2024 07h30 HE
|
Repligen Corporation
WALTHAM, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be...
Repligen to Report Third Quarter 2024 Financial Results
31 oct. 2024 07h30 HE
|
Repligen Corporation
WALTHAM, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its third quarter 2024 financial results on Tuesday, November 12,...
Repligen Opens Training & Innovation Center to Elevate Customer Experience
24 sept. 2024 07h30 HE
|
Repligen Corporation
Repligen opens Training and Innovation Center (RTIC) to support biopharma and CDMO customer experience with the company's bioprocessing technologies.
Repligen Corporation to Present at Wells Fargo Healthcare Conference
23 août 2024 07h30 HE
|
Repligen Corporation
WALTHAM, Mass., Aug. 23, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be...
Repligen Reports Second Quarter 2024 Financial Results
30 juil. 2024 07h30 HE
|
Repligen Corporation
Reports second quarter revenue of $154 millionSecond quarter orders of $157 millionBook-to-bill 1.02 for the quarter, 1.01 year-to-dateAchieved first half revenue and order targetsNarrows revenue...
Repligen Announces Agreement to Acquire Chromatography Innovator Tantti
29 juil. 2024 16h00 HE
|
Repligen Corporation
Proposed acquisition adds novel macroporous chromatography base bead technology for downstream bioprocess applicationsAccelerates expansion into new modality markets with a unique, scalable...
Repligen to Report Second Quarter 2024 Financial Results
16 juil. 2024 07h30 HE
|
Repligen Corporation
WALTHAM, Mass., July 16, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its second quarter 2024 financial results on Tuesday, July 30, 2024....
Repligen Announces CEO Transition Plan
13 juin 2024 07h00 HE
|
Repligen Corporation
WALTHAM, Mass., June 13, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that its Board of...
Repligen Corporation to Present at Upcoming June Investor Conferences
22 mai 2024 07h30 HE
|
Repligen Corporation
WALTHAM, Mass., May 22, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be...